磁共振/超声融合引导纳米颗粒定向聚焦治疗前列腺消融的多中心研究
这项前瞻性、开放标签、单臂、多中心研究纳入44例Gleason分级组1至3的局限性前列腺癌患者,采用金纳米颗粒(AuroShells)联合磁共振/超声融合引导激光激发进行光热消融。3个月和12个月靶向融合活检阴性率分别为66%(29/44)和73%(32/44),PSA从基线9.5 ng/mL显著降至3个月5.9 ng/mL和12个月4.7 ng/mL(P < .0001);最大病灶直径与12个月治疗失败几率显著相关(P = .046)。
要点
- 44例患者中3个月和12个月治疗成功率分别为66%和73%。
- PSA从基线9.5 ng/mL显著降至3个月5.9 ng/mL和12个月4.7 ng/mL(P < .0001)。
- 最大病灶直径与12个月治疗失败几率显著相关(P = .046)。
主要发现
- 基线平均PSA为9.5 ng/mL,3个月时下降5.9 ng/mL,12个月时下降4.7 ng/mL(P < .0001)。
- 3个月和12个月肿瘤学成功率分别为29/44(66%)和32/44(73%),经消融区内磁共振/超声融合活检阴性确认。
- 在Gleason分级组、MRI最大病灶直径、前列腺体积和前列腺影像报告和数据系统评分中,最大病灶直径与12个月治疗失败的几率显著相关(P = .046)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Focal therapy aims to provide a durable oncologic treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa. MATERIALS AND METHODS: A prospective, open-label, single-arm, multicenter study of men with localized PCa in Gleason Grade Group 1 to 3 was conducted. Men received a single infusion of gold nanoparticles (AuroShells), followed by magnetic resonance (MR)/ultrasound (US) fusion-guided laser excitation of the target tissue to induce photothermal ablation. MRI was used to assess the effectiveness of prostate tissue ablation at 48 to 96 hours, 3 months, and 12 months post treatment. At 3 months, a targeted fusion biopsy of the lesion(s) was conducted. At 12 months, a targeted fusion biopsy and standard templated biopsy were performed. Treatment success was determined based on a negative MR/US fusion biopsy outcome within the treated area. RESULTS: Forty-six men were enrolled in the study, and 44 men with 45 lesions completed nanoparticle infusion and laser treatment. Baseline mean PSA levels were 9.5 ng/mL, with a statistically significant decrease of 5.9 ng/mL at 3 months and 4.7 ng/mL at 12 months (P < .0001). The oncologic success rates at 3 and 12 months resulted in 29 (66%) and 32 (73%) of 44 patients, respectively, being successfully treated, confirmed with negative MR/US fusion biopsies within the ablation zone. Among Gleason Grade Group, maximum lesion diameter on MRI, prostate volume, and Prostate Imaging Reporting and Data System scoring, the maximum lesion diameter was significantly associated with the odds of treatment failure at 12 months (P = .046). CONCLUSIONS: Nanoparticle-directed focal laser ablation of neoplastic prostate tissue resulted in 73% of patients with successful treatment at 12 months post treatment, confirmed by negative MR/US fusion biopsy of the treated lesion and a systematic biopsy.
引用
- Canfield SE, George AK, Jue JS, et al. A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation. J Urol. 2024. PMID: 39226591. doi:10.1097/JU.0000000000004222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。